A safety comparison of metformin vs sulfonylurea initiation in patients with type 2 diabetes and chronic kidney disease: A retrospective cohort study

Mayo Clinic Proceedings Jan 10, 2020

Whitlock RH, et al. - Researchers performed a retrospective cohort study involving adults in Manitoba, Canada, with type 2 diabetes, who were receiving monotherapy prescription for metformin or a sulfonylurea, and a serum creatinine measurement from April 1, 2006, to March 31, 2017, in order to contrast the safety of metformin vs sulfonylureas in people with type 2 diabetes by chronic kidney disease (CKD) stage. A total of 21,996 people were involved in this cohort study (19,990 metformin users and 2006 sulfonylurea users). Findings revealed that in comparison with sulfonylureas, the use of Metformin was correlated with a lower risk for all-cause mortality (hazard ratio [HR], 0.48), cardiovascular events (HR, 0.67), and major hypoglycemic episodes (HR, 0.14). Although the appearance of CKD attenuated the mortality profit, metformin might be a safer option to sulfonylureas in people with CKD.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen